This fourth edition of the Unitaid/WHO market and technology landscape: HIV rapid diagnostic tests for self-testing report summarizes the current HIV testing gap; the challenges facing efforts to scale up; and the potential role HIV self-testing (HIVST) could play to achieve the United Nation’s 90-90-90 targets. In particular, the report synthesises the existing and emerging market demand and supply of kits.
The information in this report is intended for manufacturers, donors, national programmes, researchers and other global health stakeholders who are exploring the potential role of HIVST.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
ited. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).
The ultimate purpose of the tool is to facilitate the efficient procurement of laboratory equipment and laboratory commodities required to:
perform HIV diagnostic tests in adults, adolescent and children;
monitor treatment outcomes in patients on antiretroviral therapy.
This algorithm is addressed to laboratories
with established capacity(molecular, antigenic and/orserological) to detect dengue (DENV), Zika (ZIKV), and chikungunya(CHIKV) as part of the differential diagnosis for arborviruses. A BSL2 containment level is required to handle suspected samples.
Este algoritmo está dirigido a aquellos laboratorios que cuentan con capacidad instalada para la detección (molecular, antigénica y/o serológica) de dengue (DENV), Zika (ZIKV) y chikungunya(CHIKV),y como parte del diagnóstico diferencial para Arbovirus. Para la manipulación de muestras sospechosas, se requiere un nivel de contención BSL2